Community post

Adaptive Phage Therapeutics (APT), a clinical-stage US biotech company, just closed a $40.75 million Series B investment round led by Deerfield Management Company (and also including Mayo Clinic). This will enable APT to accelerate clinical development of their PhageBank™ phage therapies.